PreveCeutical-Backed BioGene Therapeutics Names Raj Pruthi to Board to Drive Gene Therapy Strategy

The latest announcement is out from PreveCeutical Medical ( (TSE:PREV) ).

BioGene Therapeutics Inc., in which PreveCeutical Medical is a significant shareholder, has appointed Raj S. Pruthi, MD, MHA, FACS, as a director to lead its clinical strategy and advance its gene therapy programs for metabolic diseases including diabetes and obesity. The appointment brings BioGene substantial expertise in registrational trial design, global regulatory engagement, and capital markets, as Dr. Pruthi has an extensive track record in academia and industry, including leadership roles at Relmada Therapeutics, enGene, and Johnson & Johnson, which is expected to strengthen BioGene’s clinical execution and enhance its competitive position in the gene therapy field.

Drawing on his experience overseeing multinational trials, securing regulatory approvals, and helping raise significant funding, Dr. Pruthi is expected to guide BioGene through complex late-stage development and commercialization pathways. His background in diversity, equity, and inclusion, along with a strong focus on mentorship and program-building in academic medicine, may also influence the company’s culture, talent development, and approach to patient-centered research, benefiting stakeholders across its clinical and investor communities.

The most recent analyst rating on (TSE:PREV) stock is a Sell with a C$0.02 price target. To see the full list of analyst forecasts on PreveCeutical Medical stock, see the TSE:PREV Stock Forecast page.

Spark’s Take on TSE:PREV Stock

According to Spark, TipRanks’ AI Analyst, TSE:PREV is a Neutral.

The score is driven down primarily by weak financial performance—no revenue, widening losses, cash burn—and a stressed balance sheet with negative equity and notable leverage. Technicals add downside pressure as the stock trades below key moving averages with negative MACD. Corporate events provide some offset via strategic restructuring and new financing, but they do not fully mitigate the underlying funding and execution risks.

To see Spark’s full report on TSE:PREV stock, click here.

More about PreveCeutical Medical

PreveCeutical Medical Inc. is a Vancouver-based health sciences company focused on developing innovative preventive and curative therapies using organic and nature-identical products. Through its strategic shareholding in BioGene Therapeutics Inc., the company has exposure to cutting-edge gene therapy programs targeting major metabolic disorders such as diabetes and obesity, positioning it in the broader biotech and therapeutic innovation space.

Average Trading Volume: 191,312

Technical Sentiment Signal: Sell

Current Market Cap: C$11.74M

Find detailed analytics on PREV stock on TipRanks’ Stock Analysis page.